Specialty hub

Neurology (CNS) and Pain

Containing dedicated Learning Zones, guidelines, trials and news for related conditions in Neurology (CNS) and Pain.

Read time: 5 mins

Last updated: 21st Nov 2022

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Neurology is the branch of medicine that deals with conditions and diseases involving the central nervous system (brain and spinal cord) and the peripheral nervous systems (autonomic and somatic), including their coverings, blood vessels, and all effector tissue such as muscle.

Learning Zones

Learning Zone Homepage

Multiple Sclerosis Resources

100 mins

Learning Zone Homepage

Biomarker innovation in Alzheimer’s disease Learning Zone

60 mins

Learning Zone Homepage

Anticoagulation Therapy for Stroke Prevention

300 mins

Learning Zone Homepage

Multiple Sclerosis (MS) Learning Zone

160 mins

Learning Zone Homepage

One Neuroscience and Pain Learning Zone

830 mins

Myocardium Cardiac muscle fibers banner image

Pompe Disease: Key findings from WMS 2022

Review developments in Pompe disease, expert opinion and discussion, and more in the following pages. Highlights and forthcoming expert content focus on the 2022 World Muscle Society Congress which was held in Halifax, Canada 11–15 October.

Learn more

Key developments in amyloidosis from ISA 2022

Read about the latest research on and management of amyloidosis with highlights from the 18th International Symposium on Amyloidosis (ISA) 2022 from Heidelberg, Germany, and an interview with AL amyloidosis expert Professor Giovanni Palladini.

Read now

Hot Topics in MS Research

Join Dr Jiwon Oh, Dr Enrique Alvarez and Dr Gregory Wu, as they explore our growing understanding of MS and the development of novel strategies for the management of this disease.

Watch now

Neurology encompasses over 5000 neurological diseases and relies on insights from fields such as neuroscience. This medical speciality deals with dementia including Alzheimer’s disease, Parkinson’s disease, neuromuscular disorders including spinal muscular atrophy and pain management as a sub-speciality.

Diseases in this section

Attention Deficit Hyperactivity Disorder (ADHD)

Containing relevant Learning Zones, guidelines, trials and news.

Dementia

Containing relevant Learning Zones, guidelines, trials and news.

Depression

Containing relevant Learning Zones, guidelines, trials and news.

Epilepsy

Containing relevant Learning Zones, guidelines, trials and news.

Herpes Zoster

Containing relevant Learning Zones, guidelines, trials and news.

Neuromuscular Disorders

Containing relevant Learning Zones, guidelines, trials and news.

Pain

Containing relevant Learning Zones, guidelines, trials and news.

Parkinson's Disease

Containing relevant Learning Zones, guidelines, trials and news.

Opioid prescribing for chronic noncancer pain in general practice

How should general practitioners assess patient pain and consider treatment? Read our original article investigating current advice and good clinical practice.

Learn more

Related news and insights

Drug news

Positive top-line clinical results in phase II study evaluating simufilam in Alzheimer’s disease

Cassava Sciences, Inc. announced positive top-line Phase II results for simufilam, its oral drug candidate for Alzheimer’s disease dementia

4 mins

Drug news

FDA issues Complete Response Letter for accelerated approval of donanemab for treatment of early symptomatic Alzheimer's disease

Eli Lilly and Company announced the FDA has issued a complete response letter for the accelerated approval submission of donanemab for the treatment of early symptomatic Alzheimer's disease due to the limited number of patients with at least 12 months of drug exposure data provided in the submission. No other deficiencies in the application were noted

1 min

Drug news

Mesdopetam phase IIb top-line data as a treatment for Parkinson’s disease levodopa-induced dyskinesias

IRLAB Therapeutics has announced top-line data from its Phase IIb trial investigating mesdopetam as a treatment for Parkinson’s disease levodopa-induced dyskinesias (PD-LIDs)

1 min

See all news

Related Drugs

FDA Hero Banner - Multi-coloured pills and tablets

LIDOCAINE HCI AND EPINEPHRINE EPINEPHRINE BITARTRATE .01 mg/mL HF Acquisition Co LLC, DBA HealthFirst

5 mins

Pramipexole Dihydrochloride PRAMIPEXOLE DIHYDROCHLORIDE 1.5 mg/1 Alembic Pharmaceuticals Limited

2 mins

ROPIVACAINE HYDROCHLORIDE ROPIVACAINE HYDROCHLORIDE 10 mg/mL Baxter Healthcare Corporation

4 mins

ROPINIROLE HYDROCHLORIDE ROPINIROLE HYDROCHLORIDE .25 mg/1 Major Pharmaceuticals

2 mins

AUVELITY BUPROPION HYDROCHLORIDE 105 mg/1 Axsome Therapeutics, Inc.

2 mins

Neostigmine Methylsulfate NEOSTIGMINE METHYLSULFATE 1 mg/mL Fresenius Kabi USA, LLC

3 mins

Bupropion Hydrochloride (XL) BUPROPION HYDROCHLORIDE 150 mg/1 PD-Rx Pharmaceuticals, Inc.

4 mins

Bupropion Hydrochloride (XL) BUPROPION HYDROCHLORIDE 300 mg/1 PD-Rx Pharmaceuticals, Inc.

4 mins

Donepezil Hydrochloride DONEPEZIL HYDROCHLORIDE 5 mg/1 Bryant Ranch Prepack

1 mins

Bupropion BUPROPION HYDROCHLORIDE 200 mg/1 Bryant Ranch Prepack

3 mins

Baclofen BACLOFEN 20 mg/1 Cadila Healthcare Limited

1 mins

Baclofen BACLOFEN 5 mg/1 Cadila Healthcare Limited

1 mins

Baclofen BACLOFEN 10 mg/1 Lifestar Pharma LLC

1 mins

Clomipramine Hydrochloride CLOMIPRAMINE HYDROCHLORIDE 75 mg/1 Zydus Lifesciences Limited

1 mins

Baclofen BACLOFEN 5 mg/1 Zydus Pharmaceuticals (USA) Inc.

1 mins

Related Journals

Journal

Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression

1 mins

Journal

Research Progress on Classical Traditional Chinese Medicine Jieyu Pills in the Treatment of Depression

1 mins

Journal

Vagus Nerve Stimulation For Treatment Resistant Depression: Case Series Of Six Patients - Retrospective Efficacy And Safety Observation After One Year Follow Up

1 mins

Journal

Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study

1 mins

Journal

Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response

1 mins

Journal

Serum level of soluble interleukin 6 receptor is a useful biomarker for identification of treatment-resistant major depressive disorder

1 mins

Journal

Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial

1 mins

Journal

Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression

1 mins

Journal

At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study

1 mins

Journal

Genetic comorbidity between major depression and cardio-metabolic traits, stratified by age at onset of major depression

1 mins

Related Guidelines

Guideline

Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement

These recommendations were designed to ensure safety for patients with major depressive disorder (MDD) and to aid monitoring and management of adverse effects during treatment with approved antidepressant medications. The recommendations aim to inform prescribers about both the risks associated with these treatments and approaches for mitigating such risks.

1 mins

Guideline

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use.

1 min

Guideline

Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental

Background: Clear guidance for successive antidepressant pharmacological treatments for non-responders in major depression is not well established.

1 min

See all guidelines